Shionogi & Co., Ltd.

SGIOF

OTC

16.79

USD

+0.24(+1.45%)

As of today

Overview Financials Dividends Ratios Discussions Analysis

Shionogi & Co., Ltd. fundamentals

Overview Income Statement Balance Sheet Cash Flow

Key ratios

P/E Ratio

12.35

Price/Book

1.59

Debt/Equity

1.61%

Return on Equity

12.93%

Dividend Yield

2.25%

EBITDA

230.71B

Shionogi & Co., Ltd. engages in the research, development, manufacture, and distribution of pharmaceuticals, diagnostic reagents, and medical devices in Japan. It offers Fetroja, a multidrug-resistant for gram-negative bacterial infection treatment; Xofluza, an influenza virus drug; and Tivicay for HIV treatment. It also develops Symproic for opioid-induced constipation treatment; S-120083 for Inflammatory pain; S-010887 for Neuropathic pain; S-117957 for Insomnia; sivopixant for Neuropathic pain, Sleep Apnea Syndrome, and Refractory/unexplainedchronic cough; S-637880 for Neuropathic Low Back Pain; Zuranolone for Depression; SDT-001 for attention-deficit/hyperactivity disorder patients; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for Obesity. In addition, the company develops ADR-001 for Decompensated liver cirrhosis; S-723595 for NASH; S-588410 for Esophageal and Bladder cancer; S-488210 for Head and neck squamouscell carcinoma; S-588210 for Solid tumor; S-222611 for Malignant tumor; S-770108 for Idiopathic pulmonary fibrosis; SR-0379 for Cutaneous ulcer; S-005151 for Stroke and Epidermolysis bullosa; S-531011 for Solid tumor; S-0373 for Spinocerebellar ataxia; and S-600918 and S-217622 for COVID-19, as well as S-555739 for Control of the aggravation of COVID-19. Further, it offers antibody test kits for COVID-19. Shionogi & Co., Ltd. has collaboration agreements with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University to develop antimalarial drugs. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is headquartered in Osaka, Japan.

Statements Highlights

AnnualQuarterly

Period Ending	Mar 31, 2021	Mar 31, 2022	Mar 31, 2023	Mar 31, 2024	Mar 31, 2025
Total Revenue	297,177,000,000	335,138,000,000	426,684,000,000	435,081,000,000	438,268,000,000
Gross Profit	244,654,000,000	279,723,000,000	364,438,000,000	377,479,000,000	374,441,000,000
Operating Income	117,438,000,000	110,312,000,000	149,003,000,000	153,310,000,000	156,603,000,000
Net Income	111,858,000,000	114,185,000,000	184,965,000,000	162,030,000,000	170,435,000,000
Total Assets	998,992,000,000	1,150,601,000,000	1,311,800,000,000	1,416,918,000,000	1,535,349,000,000
Total Current Liabilities	100,180,000,000	124,396,000,000	158,552,000,000	133,907,000,000	129,392,000,000
Total Equity	864,550,000,000	993,285,000,000	1,121,878,000,000	1,252,562,000,000	1,362,496,000,000
Free Cash Flow	76,095,000,000	70,504,000,000	140,680,000,000	126,017,000,000	143,357,000,000
Cash from Operations	109,039,000,000	102,068,000,000	177,867,000,000	154,284,000,000	195,460,000,000
Cash from Investing	-5,261,000,000	-96,204,000,000	-48,292,000,000	5,922,000,000	-116,080,000,000
Cash from Financing	-43,891,000,000	-36,615,000,000	-84,123,000,000	-126,853,000,000	-64,908,000,000
Net Change in Cash	67,312,000,000	-21,753,000,000	54,804,000,000	48,866,000,000	16,705,000,000